@article{ede45dd0a14c471fb984ce57ab7c9f52,
title = "Melioidosis in a patient on monoclonal antibody therapy for psoriatic arthritis",
abstract = "Melioidosis is caused by the environmental bacterium Burkholderia pseudomallei and can present with severe sepsis. Predisposing risk factors are present in 80% of cases. Monoclonal antibodies are increasingly prescribed for varied medical conditions. This report describes the first known case of melioidosis in a patient whose only risk factor for disease is treatment with a monoclonal antibody. Prescribers of monoclonal antibodies and other immunosuppressants should ensure that their patients are aware of the potential risk of melioidosis prior to travel and the precautions that should be taken. ",
keywords = "adalimumab, amoxicillin plus clavulanic acid, ceftazidime, cotrimoxazole, doxycycline, etanercept, ustekinumab, antiinfective agent, antirheumatic agent, monoclonal antibody, adult, agitation, Article, backache, Burkholderia pseudomallei, case report, chronic pain, computer assisted tomography, coughing, crackle, disease exacerbation, drug megadose, drug substitution, drug treatment failure, drug withdrawal, dyspnea, eradication therapy, fever, headache, human, infection risk, leukoencephalopathy, male, melioidosis, middle aged, myalgia, neck pain, nuclear magnetic resonance imaging, psoriasis, psoriatic arthritis, risk assessment, Arthritis, Psoriatic, immunology, isolation and purification, microbiology, risk factor, treatment outcome, Amoxicillin-Potassium Clavulanate Combination, Anti-Infective Agents, Antibodies, Monoclonal, Humanized, Antirheumatic Agents, Humans, Male, Melioidosis, Middle Aged, Risk Factors, Treatment Outcome, Trimethoprim-Sulfamethoxazole Combination",
author = "Commons, {Robert James} and R Grivas and Bart Currie",
year = "2014",
month = dec,
doi = "10.1111/imj.12610",
language = "English",
volume = "44",
pages = "1245--1246",
journal = "Internal Medicine Journal",
issn = "1444-0903",
publisher = "Wiley-Blackwell",
number = "12a",
}